Subcutaneous Levetiracetam Application Sustains Therapeutic Drug Levels

We report on a patient suffering from seizures caused by cerebral metastases of adenocarcinoma the lung. Initially, was treated effectively with oral levetiracetam. As disease progressed, intake no longer possible. Since levetiracetam had controlled patient's well, medication delivery mode switched first to intravenous application, followed return administration. After further deterioration, subcutaneous application used control epileptic symptoms while avoiding sedating effects midazolam. Subcutaneous allowed for stable seizure in end-of-life situation. Serum levels were assessed all conditions and demonstrate that therapeutic drug can be reached application. This tertiary care center Switzerland adds sparse but growing evidence base use manage palliative care.